Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-year open-label multicenter evaluation of deferasirox in transfusion-induced iron overload
2015-003531-35Phase 4
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in Transfusional Siderosis, myelodysplastic syndrome (MDS), Thalassaemia and 1 more, sponsored by Novartis. Primary endpoint: Change in serum ferritin level from baseline.
02
Drugs
deferasirox
03
Conditions
Transfusional Siderosismyelodysplastic syndrome (MDS)Thalassaemiaanaemia
Beyond the preview
Go deeper on 2015-003531-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003531-35.